AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 92 min read$LLY

Lilly Study Shows Broader Biomarker Changes With Taltz-Zepbound Combination In Psoriasis

Eli Lilly (LLY) presented data from its Phase 3b TOGETHER-PsO trial, showing that combining Taltz (psoriasis treatment) with Zepbound (obesity therapy) led to broader biomarker changes than Taltz alone. The study suggests interconnected immune and metabolic pathways in patients with both psoriasis and obesity. LLY stock closed at $1,169.60, down 1.61%.

Original reporting
rttnews.com
Published Oct 9, 2026, 1:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 1:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Lilly Study Shows Broader Biomarker Changes With Taltz-Zepbound Combination In Psoriasis — source image
Source · rttnews.com
Decision brief

The 30-second read

$LLYBearishMed
01

Why it matters

The exploratory biomarker data provide early scientific insight but do not yet translate into a clear commercial advantage, limiting immediate market impact.

02

Market read

First‑report of new trial biomarker data; modest price reaction; limited immediate trading opportunity.

03

What to watch

Potential future label expansion and cross‑indication synergies between Taltz and Zepbound may not be fully priced yet.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Lilly's Taltz is an approved psoriasis therapy; Zepbound is approved for chronic weight management. The combination is being explored for patients with both conditions.

Company-level read

Ticker impact

$LLYBearishHigh confidence
Context

Eli Lilly presented new Phase 3b data showing broader biomarker changes with the Taltz‑Zepbound combo in psoriasis patients.

Expected impact

likely modest pressure as investors price in the incremental data without a clear efficacy breakthrough

Evidence & confidence

The trial results are a first‑report but show only broader biomarker changes, not a decisive efficacy win; the stock already fell ~1.6%.

Market effects

Sector

Adds data to the immunometabolic space, may influence other biotech firms developing combo therapies for inflammatory diseases.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Modest, as the data are specific to Lilly's pipeline.

Counterpoint

What could challenge this read

The broader biomarker response could be a stepping stone to a differentiated indication, offering upside if later data show clinical benefit.

Key entities

  • Company
    Eli Lilly and Company

    Pharmaceutical company presenting the trial data.

  • Drug
    Taltz

    Lilly's psoriasis treatment.

  • Drug
    Zepbound

    Lilly's obesity therapy.

Read at source← All news

StoryEli Lilly reports broader biomarker changes with Taltz‑Zepbound combo in psoriasis‑obesity trial

Also covered by

4 outlets

Related articles

OCT 9
$LLYMed

Eli Lilly's Dual Therapy Shows Promise in Psoriasis and Metaboli

Eli Lilly's phase 3b TOGETHER-PsO trial showed its combination treatment of Taltz and Zepbound improved outcomes for patients with moderate-to-severe plaque psoriasis who are overweight or obese. The company's GF Value™ suggests it is modestly undervalued with a 25.4% margin of safety, and its GF Score™ is 98 out of 100, indicating strong financial health. Insiders have been net sellers, while 25 premium gurus hold LLY, with 12 adding and 10 trimming positions.

gurufocus.com2 min
OCT 9
$LLYMed

Eli Lilly And Company Announces New Exploratory Phase 3b Data On Taltz And Zepbound In Adults With Psoriasis And Obesity

Eli Lilly presented data from the TOGETHER-PsO Phase 3b trial showing that combining Taltz (ixekizumab) and Zepbound (tirzepatide) led to broader biomarker responses in adults with psoriasis and obesity compared to Taltz alone. The trial, presented at the 2026 Fall Clinical Dermatology Conference, found greater reductions in inflammatory immune activity with the combination treatment.

marketscreener.com2 min
OCT 9
$LLYMed

New data for Eli Lilly and the Taltz-Zepbound combination

Eli Lilly presented new data from a Phase 3b trial showing that the combination of Taltz and Zepbound may benefit obese or overweight psoriasis patients. The company claims the results support a more integrated treatment approach for these patients, addressing both immunological and metabolic aspects. According to Lilly, psoriasis and obesity often coexist in 61% of U.S. patients.

marketscreener.com2 min
OCT 9
$LLYMedAI 9/10

New Weight-Loss Drug Helps People With Type 2 Diabetes Lose 21% of Their Body Weight

Eli Lilly's experimental drug, retatrutide, helped Type 2 diabetes patients lose 20.8% of their body weight in an 80-week trial. The highest dose group saw an average weight reduction of 49.6 pounds. The drug also improved blood sugar control, with 40% of participants on the two highest doses achieving normal blood sugar levels. The results were presented at the European Association for the Study of Diabetes meeting and published in The Lancet.

zmescience.com2 min
OCT 9
$LLYMedAI 8/10

Lilly Highlights Immune And Metabolic Effects Of Taltz Plus Zepbound

Eli Lilly reported Phase 3b data showing combined Taltz and Zepbound treatment led to broader changes in psoriasis-related, immune, and metabolic biomarkers compared to Taltz alone. The study involved adults with psoriasis and obesity or overweight. LLY closed at $1,169.60, down 1.61%, and is down 0.51% in pre-market trading.

rttnews.com2 min